Herbal Drug BNO 1016 Versus Fluticasone Propionate Nasal Spray in the Treatment of Chronic Rhinosinusitis without Nasal Polyps: A Preliminary Report

Aleksandar Perić; Dejan Dejan; Aleksandra Aleksić; Gabriela Kopacheva-Barsova; Aneta V. Perić

doi:10.5152/eurjther.2020.19117

Authors

Aleksandar Perić Department of Otorhinolaryngology, Military Medical Academy Faculty of Medicine, University of Defense, Crnotravska 17, Belgrade https://orcid.org/0000-0002-8453-7272
Dejan Dejan ENT Hospital “Dr. Žutić”, Belgrade https://orcid.org/0000-0002-5377-1525
Aleksandra Aleksić Department of Otorhinolaryngology, University Hospital of Banja Luka Clinical Center, Banja Luka https://orcid.org/0000-0001-7860-2763
Gabriela Kopacheva-Barsova Department of Otorhinolaryngology, University Hospital “St. Mother Theresa”, Skopje https://orcid.org/0000-0002-2917-7921
Aneta V. Perić Institute for Pharmacy, Military Medical Academy Faculty of Medicine, University of Defense, Crnotravska 17, Belgrade https://orcid.org/0000-0002-4187-7584

DOI:

https://doi.org/10.5152/eurjther.2020.19117

Keywords:

Glucocorticoids, ınflammation, plants, medicinal, rhinitis, sinusitis

Abstract

Objective: Current evidence supports the use of herbal drugs in the reduction of symptoms of acute (ARS) and chronic rhinosinusitis (CRS). Intranasal corticosteroids are the first line treatment option for treating CRS with or without nasal polyps. This study was designed to compare the safety and efficacy of plant medication BNO 1016 and fluticasone propionate nasal spray (FPNS) for treating CRS without nasal polyps (CRSsNP).
Methods: Forty subjects with CRSsNP were randomly divided into two treatment groups that comprised 20 patients each. The patients from Group 1 were treated with herbal drug BNO 1016, tablets of 160 mg, 3×1/d per os, for 28 d. The patients from Group 2 used FPNS 200 μg once daily, 2 puffs in each nostril in the morning for 28 d. We evaluated the nasal total symptom score (TSS), individual scores for each symptom (nasal congestion/obstruction, rhinorrhea/postnasal discharge, facial pain with the sense of pressure, headache, loss of the sense of smell), total endoscopic score (TES), and individual endoscopic signs (edema of the nasal mucosa, nasal secretion, and nasal crusting), before and after the therapy.
Results: TSS was lower on Day 7 (p=0.008), Day 14 (p=0.004), Day 21 (p<0.001), and Day 28 (p=0.002) in patients treated with BNO 1016. Moreover, the TES was lower on Day 21 (p=0.001) and Day 28 (p=0.002) in subjects who were on therapy with BNO 1016. No adverse events were noted in Group 1; however, in patients treated with intranasal glucocorticoids, 2 patients reported mild nasal bleeding, and 1 reported a sense of dryness in the nose.
Conclusion: BNO 1016 could be a good alternative to intranasal corticosteroids in the treatment of CRSsNP without adverse events.

Metrics

Metrics Loading ...

References

Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016; 6: S1-213.

Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50: 1-12.

Prokopakis EP, Vlastos IM, Ferguson BJ, Scadding G, Kawauchi H, Georgalas C, et al. SCUAD and chronic rhinosinusitis. Reinforcing hypothesis driven research in difficult cases. Rhinology 2014; 52: 3-8.

Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope 2015; 125: 1547-56.

Günel C, Başak HS, Bleier BS. Oral steroids and intraoperative bleeding during endoscopic sinus surgery. B-ENT 2015; 11: 123-8.

Jund R, Mondigler M, Stammer H, Stierna P, Bachert C. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol 2015; 135: 42-50.

Passali D, Cambi J, Passali FM, Bellussi LM. Phytoneering: a new way of therapy for rhinosinusitis. Acta Otorhinolaryngol Ital 2015; 35: 1-8.

Yaremchuk S, Zabolotny D, Vareniuk I, Makarchuk N, Veselsky S. Sinupret® oral drops protect against respiratory epithelium atrophy in experimental acute rhinitis. Clinical Phytoscience 2015; 1: 8.

Popovich VI, Koshel IV. Sinupret® as add-on therapy to saline irrigation for children with acute post-viral rhinosinusitis. Clinical Phytoscience 2017; 3: 10.

Richstein A, Mann W. Treatment of chronic rhinosinusitis with Sinupret. Schweiz Zschr Ganzheits Medizin 1999; 11: 280-3.

Palm J, Steiner I, Abramov-Sommariva D, Ammendola A, Mitzenheim S, Steindl H, et al. Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis. Rhinology 2017; 55: 142-51.

Glatthaar-Saalmüller B, Rauchhaus U, Rode S, Haunschild J, Saalmüller A. Antiviral activity in vitro of two preperations of the herbal medicinal product Sinupret® against viruses causing respiratory infections. Phytomedicine 2011; 19: 1-7.

Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993; 31: 183-4.

Pfaar O, Mullol J, Anders C, Hörmann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology 2012; 50: 37-44.

Devillier P, Brüning H, Bergmann K-Christian. Determination of the minimally important difference in a nasal symptom score in house dust mite allergy. Allergy 2019; 74: 2191-8.

Passali D, Loglisci M, Passali GC, Cassano P, Rodriguez HA, Bellussi LM. A prospective open-label study to assess the efficacy and safety of a herbal medicinal product (Sinupret) in patients with acute rhinosinusitis. ORL J Otorhinolaryngol Relat Spec 2015; 77: 27-32.

Rossi A, Dehm F, Kiesselbach C, Haunschild J, Sautebin L, Werz O. The novel Sinupret® dry extract exhibits anti-inflammatory effectiveness in vivo. Fitoterapia 2012; 83: 715-20.

Virgin F, Zhang S, Schuster D, Azbell C, Fortenberry J, Sorscher EJ, et al. The bioflavonoid compound, Sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010; 120: 1051-6.

Kreindler JL, Chen B, Kreitman Y, Kofonow J, Adams KM, Cohen NA. The novel drug extract BNO 1011 stimulates chloride transport and ciliary beat frequency in human respiratory epithelial cultures. Am J Rhinol Allergy 2012; 26: 439-43.

Akpinar ME, Yigit O, Akakin D, Sarioz O, Ozkan N, Yildiz SD, et al. Topical glucocorticoid reduces the topical decongestant-induced histologic changes in an animal model nasal mucosa. Laryngoscope 2012; 122: 741-6.

Cho DY, Skinner D, Mackey C, Lampkin HB, Elder JB, Lim DJ, et al. Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis. Int Forum Allergy Rhinol 2019; 9: 629-37.